KRISTEN HORN: Open Payments
NPI 1710723473 · CAPE GIRARDEAU, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,861 in 85 payments from 12 companies in 2025. Trend: 2023 $0 · 2024 $42 · 2025 $1,861
Food & beverage: $1,861
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 34 | $638 |
| Janssen Biotech, Inc. | 16 | $295 |
| Madrigal Pharmaceuticals | 6 | $216 |
| PFIZER INC. | 6 | $176 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 7 | $140 |
| GENZYME CORPORATION | 4 | $101 |
| LUMENDI LLC | 1 | $68 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $68 |
| Regeneron Healthcare Solutions, Inc. | 2 | $67 |
| Phathom Pharmaceuticals, Inc. | 2 | $39 |
Products named: RINVOQ, TREMFYA, REZDIFFRA, DUPIXENT, VELSIPITY, XIFAXAN, SKYRIZI, LINZESS.
Industry payments across MO — which companies pay providers there.
